Clinical trial · Interventional
Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours
A Phase I Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the PI3K Inhibitor WX-037, Given as a Single Agent and in Combination With the MEK Inhibitor WX-554, in Patients With Solid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study terminated for business reasons
Summary
Brief summary (as posted)
The purpose of this study is to test the safety of escalating doses of the novel PI3K inhibitor WX-037 and to explore its effectiveness in combination with WX-554 which targets mitogen activated protein kinase (MEK1 and MEK2). Preclinical evidence indicates that these two novel compounds could provide targeted inhibition of both pathways to block tumour growth.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumours | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| WX-037 | Drug | — | UNRESOLVED |
| WX-554 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- WX-037
- description
- PI3K inhibitor
- interventionNames
- Drug: WX-037
- type
- EXPERIMENTAL
- label
- WX-037 in combination with WX-554
- description
- PI3K inhibitor in combination with MEK inhibitor
- interventionNames
- Drug: WX-037
- Drug: WX-554
Primary outcomes (2)
- measure
- Incidence of Dose limiting toxicities
- timeFrame
- during cycle 1 (21days) of treatment with WX-037
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with advanced, metastatic and/or progressive solid tumors for whom there is no effective standard therapy available (for part 2 in addition patients for whom their PI3K pathway is deregulated) * Evaluable or measurable disease * Has normal organ function; is no greater than 2 on the ECOG performance scale * Negative hCG test in women of childbearing potential Exclusion Criteria: * History of diabetes requiring daily medication or history of grade 3 or more fasting hyperglycemia * Patients with major surgery, radiotherapy, or immunotherapy within 4 weeks of starting the study * Clinical significant, unresolved toxicity from previous anti-cancer therapy * Patients who previously received a MEK inhibitor (for combination part only) * Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs * Known medical history of retinal vein occlusion, intraocular pressure greater than 21 mm Hg or patient considered at risk of retinal vein thrombosis (combination part only) * Known HIV positivity or active hepatitis B or C infection * History of clinically significant cardiac condition
References
Publications (0)
Data not yet available